Popular on TelAve
- L2 Aviation Announces Strategic Growth Investment from Argentum
- Desert Water SL and Planet Alpha Corp. map carbon for the country of Sierra Leone using satellite data for conservation and the creation of carbon
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- Hoffman Homes Unveils New Brand
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Zoiko Telecom joins BT Wholesale's Partner Plus to bring enhanced connectivity to UK customers
- Phoenix Theory Unveils Revolutionary Perspective on Quantum Entanglement, Causality and Particle Physics
- BroadSource and Evolve IP – A Shared Vision for Secure Payments by Phone
- Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression NRx Pharmaceuticals: NRXP
- Energies Media: Unifying Insights Across the Energy Spectrum
Similar on TelAve
- AVTECH Announces New Room Alert Bundles for Heat Safety and Enhanced Indoor Air Quality Monitoring
- Introducing MyTennisTrip.com: Your Ultimate Tennis Travel Companion
- NEMTAC Announces New Board of Directors Officers for 2024-2025
- CCHR: "Family Estrangement" Used to Detain and Abuse Children in Psych Hospitals
- NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
- College Campus Safety: The Importance of Self Defense Keychains for Women
- CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
- DocVilla Introduces Best All-in-One Customizable Cloud-Based EHR Practice Management Software for Multi-Specialty and Small Practices
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- Cooking with Claudine Re-Launches in September with Fresh, Organic, and Gluten-Free Meal Delivery in the San Francisco Bay Area
NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment
TelAve News/10838813
EXCELSIOR, Minn. - TelAve -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on TelAve News
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on TelAve News
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on TelAve News
- Introducing MyTennisTrip.com: Your Ultimate Tennis Travel Companion
- Award-Winning Writer Thrills Mystery Lovers with The Button Collector on September 17
- Tobu Railway Group's Tobu Kogyo Division Has Renovated the Kotoku Cattle Farm in Nikko National Park and Reopened it as of July 1, 2024
- Mytee Products' Big Move: More Space Equals Exciting New Products
- Alice's Lullaby Set for an October 8, 2024, Launch
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on TelAve News
- Webinar Announcement: Creative Methods for Tracing Assets
- NEMTAC Announces New Board of Directors Officers for 2024-2025
- Dehy Mills Welcomes Two New Board Members to Support Future Growth
- Stars of Netflix's 'Skywalkers:A Love Story' Scale World's Tallest Bridge Inspired by $DOGS Community
- CCHR: "Family Estrangement" Used to Detain and Abuse Children in Psych Hospitals
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on TelAve News
- CWP announces full OTS (One Touch Switching) readiness
- Aortem, Backed by Venturseed, Transforms Mobile and Gaming Development with an Open Source Platform and Expanding Developer Tools
- NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
- Hollywood In Pixels, Inc. Announces the 7th Silver Pixel Awards
- Policy vs Politics Rebrands to Everything Policy: A New Era of Facts-first Policy Content
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
- The Royalty Network and CEO Frank Liwall Appoint Daniel Abowd as New President & General Counsel
- L2 Aviation Announces Strategic Growth Investment from Argentum
- African-American Marketing Association Launches Business of Marketing Bootcamp™ for Small Businesses
- WOHLER Announces its NEW iAM1-MIX8 Next Generation MIX Series Solution @ IBC 2024
- The World's No.1 Superstar Dies After Choking on a French Fry
- Patton Announces World's Smallest Ethernet Extender: New SFP Module Extends Ethernet Up to 3.5 Miles Over Copper and Achieves Speeds up to 18 MBPS
- Award-winning and Renowned Voice Actor Nancy Cartwright to Deliver Keynote at the That's Voiceover Career Expo 2024 in Los Angeles
- "Army of Liars" Exposes How Social Media Profits from Disinformation
- Vantiva Demonstrates its Vision of the Connected Home of the Future with New Lineup of AI-Powered CPE at IBC 2024
- Challenge Arcade's World Record Weekend 2024
- Empowering Educators with AI: Goosechase and DIGITAL Partner for the Future of Interactive Experiences
- Join Us at the 136th Canton Fair from October 15th to 19th, 2024!
- Legendary Aviation Coffee Company Celebrates 2100% Growth with Exceptional Single-Origin Air-Roasted Coffee